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Background: Artemisinin-based combination therapy (ACT) has been adopted as the most effective treatment
against malaria in many endemic countries like Kenya while quinine has remained the second line. The objective of
the current study was to assess access to Kenya’s policy recommended anti-malarials, ACT and quinine in the public,
private and not-for-profit drug outlets in western Kenya.
Methods: A cross-sectional survey using purposive sampling of 288 outlets (126 public, 96 private, 66 not-for-profit)
was conducted in western Kenya in two regions with varying Plasmodium falciparum endemicities. Information on
access (availability, price, affordability) on ACT and quinine was collected using the WHO and Healthcare Associated
Infection (HAI) standardized methodologies for availability, prices and affordability of drugs. From a Ministry of
Health database, the following were included in the analyses: one (1) main public hospital, followed by random
selection of five hospitals under this main facility. Eight other public outlets under each of the hospitals were
selected, to a total of 96. Matching number of private outlets (n = 96), all (66) not-for-profit outlets and additional 30
public health facilities were sampled to get the required sample size of 288.
Results: More public 111 (88.1%) and not-for-profit 27 (40.9%) outlets stocked subsidized ACT (artemether-lumefantrine,
AL). Other artemisinin-based combinations were widely available for both children 93 (96.9%) and adults 82
(85.0%) in private outlets. Frequent stock-outs were in public in 106 (84%), reporting three times or more stock-outs
in three months. Subsidized ACT (AL) was sold at median price of USD 0.94 and 0.75 in private and not-for-profit outlets
respectively. The costs was higher than recommended price of USD 0.5 and requiring up to 0.20-0.25 days of disposable
income for households in lowest economic status.
Conclusion: There is low availability of subsidized ACT (AL) and higher frequency of stock-outs in government
facilities, while private sector sells AL at higher prices, thus making it less affordable to many households. These
factors determine the adherence to the dosing schedules during the treatment course and thus the evaluation of
the subsidy policy, its implementation and role in malaria burden in this region is compulsory.Background
Malaria still poses a great burden in many parts of
Africa despite the availability of many interventions
focused on preventive and therapeutic approaches [1].
Artemisinin-based combination therapy (ACT) has been
adopted as the most effective treatment option against
malaria in many countries following the widespread
malarial parasite resistance to more affordable anti-* Correspondence: collinouma@yahoo.com
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article, unless otherwise stated.malarial drugs, such as chloroquine and sulphadoxine-
pyrimethamine (SP) [2]. Kenya adopted the new malaria
policy in 2004, which recommends the use of arte-
mether 20 mg-lumefantrine 120 mg (AL) as the first-
line drug for treatment of uncomplicated malaria [3],
while quinine is preferred for complicated and severe
malaria.
The World Health Organization (WHO) however,
stresses the fact that many strategies to increase access
to effective anti-malarial drugs have been put in place,
but in the year 2009, less than 15% of children under-
five years of age received ACT when they presented withCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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most mortality in children who are able to attend a
health facility with adequate staff and supplies occurs
within 24 hours after admission [5]. Consequently, it is
evident that most mortality occurring in such set-ups
are as a result of delay in home management with effect-
ive drugs, thus underscoring the importance of early
treatment for preventing such mortalities [5]. It is, there-
fore, critical to improve access to recommended drugs.
One way of approaching this problem is to ensure access
to treatment using effective anti-malarials like ACT and
quinine which could be given promptly even at primary
health care facilities as highlighted by WHO, to ensure
access and minimize parasite resistance [5].
Even with the efforts to improve the case management
of malaria, the success of policy implementation and ef-
fectiveness is measured by the availability of the recom-
mended drugs at the point of care [6]. Many patients in
Africa use private sector as their primary source of med-
icines, with 50% of febrile cases reported to be treated in
this sector [7], despite the fact that the manufacturer’s
selling prices and final patient prices range from 56% to
358%, making treatment unaffordable [8]. On average,
households in many malaria endemic countries spend
up to 90% of their household expenditure on medicines,
portraying high anti-malarial pricing as an important
contributing factor to the lack of access to ACT [9]. Fur-
thermore, a recent study [10] demonstrated that there
were huge increases in quality-assured ACT (QAACT)
availability (25.8—51.9% points), and market share (15.9—
40.3% points), driven mainly by changes in the private
for-profit sector. The same study observed that large
falls in median price for QAACTs per adult equivalent
dose was seen in the private for-profit sector in six pi-
lots, ranging from US$1.28 to $4.82. The recent findings
provide additional evidence that anti-malarial pricing is
a critical factor in access to ACT in sub-Saharan African
countries.
To enhance ACT policy implementation and further
proper management of malaria, Kenya government has
scaled up case management strategies as follows: 1) all
public health institutions offer ACT free-of-charge;
2) introducing cheaper artemether-lumefantrine (AL)
to be sold at Kenyan shillings 40 (USD 0.5) in retail drug
outlets [11]; and 3) children who are below 13 years of age
are treated for free in public health facilities. Despite the
efforts to improve access, ACT remains registered as
prescription-only drug recommended for formal sector
providers [12] and, in 2010, the treatment policy was uni-
versally changed to include the use of ACT for only
laboratory-confirmed malaria cases [13,14]. The two regu-
lations hence limit access of households to these drugs
further causing delay in treatment for more than 24 hours.
However, access to ACT at the point-of-care and at thesubsidized prices at any given time, especially in malaria
endemic areas, with high levels (≥40%) of malaria preva-
lence throughout the year remains unknown [11]. Fre-
quent stock-outs have been reported in a few studies as
leading to the use of several inappropriate anti-malarials
in the households [15-18]. Availability of a particular drug
in the market is an important factor in determining which
anti-malarials are bought for use [19] of which, in addition
to high cost of anti-malarial, are important contributing
factors to lack of access [20]. Furthermore, two years fol-
lowing the Kenyan government rolling-out the subsidy
policy on ACT, namely artemether 20 mg-lumefantrine
120 mg (AL) as the first-line treatment, and quinine still
being the preferred treatment of severe malaria, no survey
has been carried out to date to evaluate availability of anti-
malarials in malaria-prone regions. Most of the studies
reporting ACT availability before or immediately after the
roll-out were based on country-wide surveys and results
were not attributed to fit the differences in regional preva-
lence of malaria.
It is on this background that the current study assessed
access to Kenya’s policy recommended anti-malarials,
ACT and quinine in the public, private and not-for-profit
drug outlets using the WHO and Healthcare Associated
Infection (HAI) standardized methodologies for availabil-
ity, prices and affordability of drugs.
Methods
Study design and study area
A cross-sectional study was conducted between February
and May 2012 in Nyanza Province in western Kenya.
Two regions, endemic for Plasmodium falciparum trans-
mission, but with different levels of risk for malaria in
the province, were targeted: the lowlands of the Province
(Kisumu, Siaya and Bondo regions) around Lake Victoria
with a holoendemic and stable P. falciparum transmis-
sion (altitude 0–1,300 metres) and Kisii highlands (Kisii,
Gucha and Nyamira regions), with an epidemic transmis-
sion (>1,300-1,750 metres) [21].
Malaria in the region accounts for 40% of out-patient
visits and 40% of hospital in-patient admissions, with be-
tween 10–15 paediatric cases of severe malaria often com-
plicated with anaemia and malnutrition, on a daily basis
[22]. Malaria transmission occurs all year round, peaking
in the rainy season months of April and May. The high-
lands areas suffer epidemic levels, where temperature in-
creases and rainfall variation impacts on vector breeding
and malaria transmission with some areas experiencing a
prevalence of up to 20% [23].
Selection of outlets and households
Three-stage sampling approach was used to select drug
outlets. For each region, a list of public medical facilities
was compiled using a database obtained from the Kenyan
Table 1 Availability of subsidized ACT (AL), other forms
of ACT and quinine in the three outlet types
Outlet type
Public
n = 126 (%)
Private
n = 96 (%)
Not-for-profit
n = 66 (%)
Availability of anti-malarial
drugs
Subsidized ACT (AL) 111 (88.1) 27 (28.1) 27 (40.9)
Other ACT 0 (0) 87 (90.6) 8 (12.0)
Quinine 59 (46.8) 68 (70.8) 36 (54.5)
ACT, artemisinin-based combination therapy, AL, artemether-lumefantrine.
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lected study areas, the main public hospital was selected,
and then five hospitals under the main facility were ran-
domly sampled. Lastly, eight other public outlets under
each of the hospitals were selected, to a total of 96. Match-
ing number of private outlets was randomly selected. All
(66) not-for-profit outlets and additional 30 public health
facilities were sampled to get the required sample size of
288. For every outlet sampled, one household served by
the outlet was sampled.
Data collection
Data was collected through drug auditing and interviews
by enumerators who visited the outlets as in pairs. Focus
was on tablet anti-malarials only – typically, since this is
the most common formulation. Prior to data collection,
enumerators who had nursing qualification were trained
on the use of the tools prior to pilot testing in nine of
each outlet type with regular supervision. Drug outlets
were recruited for the survey. In the outlets, providers
who consented to participate were asked two screening
questions to determine whether (1) the outlet had stocked
ACT or quinine, within the previous three months, and
(2) if ACT or quinine were available on the day of the sur-
vey. All providers answering “yes” to at least one of these
questions gave information about the ACT and quinine
after informed consent was obtained from them. In outlets
with more than one attendant, the provider who was
serving the clients at the time of the survey provided
the information.
The information collected in the drug outlets included
brand name, amount in stock and the frequency of stock
out in the last three months, retail price, and dosage
form as well as information on packs per weight group.
The price of anti-malarials was originally collected in
Kenya Shillings (KES), and then later converted to US
dollars (USD) for international standardization in costs.
Data management and statistical analysis
Data collected was checked in the field and at the end of
each day cleaned to ensure completeness, consistency,
credibility and eligibility. Information captured in audit
sheets and interview guide on availability, affordability
and prices of anti-malarials as well as their use in house-
holds was coded and entered into Statistical Package for
Social Sciences (SPSS) version 19. Analysis adopted the
WHO and Healthcare Associated Infection (HAI) stan-
dardized methodologies for availability, prices and af-
fordability of drugs. Data from the outlets were grouped
into three categories and analyzed separately into: 1)
public outlets, 2) private outlets and 3) not-for-profit
outlets. Furthermore, anti-malarials were stratified as the
government subsidized ACT (AL), other formulations of
ACT and quinine. Using the mean and median, drugaccess (price, availability and affordability) was established.
For the availability analysis, different dose strengths of
the same drug were combined to calculate the overall
availability of that particular anti-malarial on the day of
the survey.
The median prices of anti-malarials were calculated
for each anti-malarial category identified. For compari-
son, the median price ratios (MPR) of the ACT median
price to the current government recommended price for
a single treatment course with AL was computed in pri-
vate and not-for-profit outlets at USD 0.5 (KES 40). For
quinine, the MPR of private to not-for-profit outlets was
calculated, since there was no government-subsidized
price at the moment.
Affordability was expressed as the number of days
households with lowest daily disposable income level at
KES 150,USD 1.875 [16] would need to work in order to
pay for the full adult dose of treatment course with AL,
other artemisinin-based combinations and quinine avail-
able in the outlet. Chi-square analyses were used for




All outlets stocked more than one category of anti-
malarial. More public 111 (88.1%) and not-for-profit out-
lets 27 (40.9%) surveyed stocked AL, the recommended
first-line treatment for uncomplicated malaria. However,
less than a third of the private outlets 27 (28.1%) had
stocked AL (Table 1). Other forms of ACT were stocked
mostly by private outlets 87 (90.6%) and less by not-for
profit 8 (12%), while public outlets did not stock any
other ACT. All outlets stocked both first-line subsidized
ACT (AL) and second-line (quinine) anti-malarials in
varied proportions (Table 1).
Availability of packs per weight group of subsidized ACT,
other forms of ACT and quinine tablet formulation
The subsidized ACT was available in all the four weight-
specific presentations in less than half of the total outlets
88 (30.6%), while quinine was available in 137 (47.6%)
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both children 93 (96.9%) and adults 82 (85.0%) in private
outlets. The availability varied with the outlet type as
shown in Table 2. Availability of packs for different weight
groups was also evaluated for AL in the three outlet types.
The six tablet pack was in stock in more public outlets 47
(37.3%) than in private 21 (21.9%) and not-for profit 16
(24.2%) outlets (Table 2). The same trend was observed
for the twelve AL tablet packs, however, the eighteen pack
was in stock in public 66 (52.4%) and not-for-profit 33
(50.0) than in private 12 (12.5%) outlets. Apparently, a
higher proportion of quinine tablet formulation was
available in private 46 (47.9%) than in public 44 (34.9%)
and not-for-profit 28 (42.4%) outlets (Table 2).
Stock-out of anti-malarials
Stock-out in the past three months was defined as ab-
sence of drugs from stock for at least seven consecutive
days [25]. The stock-out rates in public outlets was most
frequent in the last three months with 106 (84.0%) out-
lets reporting three times or more stock-outs. On the
other hand, private sector suffered stock-outs once in
three months in 70 (73.0%) outlets while in not-for-
profit outlets, there was no stock-out in 57 (87.0%) in
the past three months.
The decision for restocking a particular anti-malarial
was mainly mediated by the recommendation by the
government in 158 (54.7%) outlets followed by consumer
demand in 73 (25.5%) outlets. The government recom-
mendation guided decision for restocking in both public
in 125 (99.5%) and not-for-profit in 51 (76.7%) outlets
while private outlets restocked depending on most prof-
itable in 57 (59.2%) and consumer demand in 25 (26.3%)
among other reasons.
The price of anti-malarials
Anti-malarials in the public outlets were provided for free
and were not included in the price analysis. Prices of anti-
malarials with the same generic names were recorded andTable 2 Availability of packs per weight group of subsidized
Outlet type
Public n = 126 (%)
All the four AL weight specific packs 53 (42.1)
AL 6 tablet pack for 5-14 kg 47 (37.3)
AL 12 tablet pack for15-24 kg 62 (49.2)
AL 18 tablet pack for 25-34 kg 66 (52.4)
AL 24 tablet pack for ≥35 kg 111 (88.1)
Other forms of ACT for children 0
Other forms of ACT for adults 0
Quinine (tablet formulation only) 44 (34.9)
ACT, Artemisinin-based Combination Therapy, AL, Artemether-Lumefantrine.median prices were computed. The overall median prices
for AL, other forms of ACT and quinine were USD 0.94
(R = 0.63-1.25), USD 5.63 (R = 1.88-8.13) and USD 1.25
(R = 0.75-1.25), respectively. The median price for all
anti-malarials categories was much higher in private
outlets than in not-for-profit outlets, as shown in Table 3.
Other forms of ACT were more highly priced than the
subsidized ACT and quinine.
The median price ratio (MPR) for other forms of ACT
was computed using the government subsidized price of
ACT of USD 0.5. The private outlets had higher MPR
for other forms of ACT compared to their not-for-profit
counterparts (Table 3). Although AL was available in all
the outlet types, the government recommended price of
USD 0.5 did not apply and AL was sold at median price
of USD 0.94 (R = 0.63-1.25) and USD 0.75 (R = 0.63-1.0)
in private and not-for-profit outlets, respectively. Other
forms of ACT were on average 12 times higher in price
than AL in private outlets and five times higher in not-
for-profit outlets (Table 3).
Affordability of anti-malarials
All the anti-malarials were more affordable in not-for-
profit outlets than private outlets. The quinine pur-
chased within not-for-profit outlets was most affordable
to household with lowest disposable income levels
(Table 4). Other forms of ACT were least affordable and
would cost up to 3.20 days of disposable income in pri-
vate outlets.
Discussion
The current study was designed to assess access to Kenya’s
policy recommended anti-malarials, ACT and quinine in
the public, private and not-for-profit drug outlets using
the WHO and Healthcare Associated Infection (HAI)
standardized methodologies for availability, prices and
affordability of drugs. The findings of the current survey
revealed that the government-recommended anti-malarials
were available in all outlet types with public outletsACT (AL)
Private n = 96 (%) Not-for-profit n = 66 (%)
23 (23.9) 12 (18.2)
21 (21.9) 16 (24.2)
25 (26.0) 12 (18.1)
12 (12.5) 33 (50.0)
42 (43.8) 46 (69.7)
93 (96.9) 8 (12.1)
82 (85.0) 9 (13.6)
46 (47.9) 28 (42.4)
Table 3 Median prices and Median Price Ratios of anti-malarials being sold in private and not-for-profit outlets
Outlet type
Anti-malarials Private Not-for-profit
Median price (range) USD Median price ratio Median price (range) USD Median price ratio
AL* 0.94 (0.63-1.25) 1.88 0.75 (0.63-1.00) 1.5
Other forms of ACT** 6.0 (1.88-10.63) 12 2.5 (1.88-3.13) 5
Quinine* 1.0 (0.75-1.25) 1.33 0.75 (0.63-1.13) 1
USD, United States Dollars; ACT, artemisinin-based combination therapy; AL, artemether-lumefantrine.
*Median price ratio was calculated using median price of quinine in not-for-profit as reference since there is no government subsidized price.
**Median price ratio was calculated as anti-malarial median price to the government recommended price of subsidized ACT (AL) (KES 40, USD 0.5).
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malarials; subsidized ACT (AL) and quinine. The pri-
vate outlets on the other hand had stocked various
other Artemisinin-based combinations in addition to
the policy recommended anti-malarials. Stocking other
forms of ACT in private outlets could be due to the fact
that selling subsidized ACT would be unprofitable.
Other studies in the region similar to the current study
site (in terms of malaria endemicity) showed that pri-
vate sectors prefer stocking drugs which can retail at
competitive prices [26]. This is a matter of concern
given that many households in the current study bought
drugs from private outlets, where anti-malarials were
sold at higher prices.
Low availability of all the four weight-specific packs of
AL is of more concern, and worse still, the low availabil-
ity of the six-tablet Pack meant for the treatment of
under-fives, which is the most vulnerable group due to
malaria infections. Coupled with the higher frequency of
stock-outs recorded in this study, the calculation of
appropriate regimen may not be guaranteed when the
right package size is lacking, especially with low know-
ledge of providers on AL regimen in the private outlets
as observed in a previous study in this region [27]. For
example, giving four packets of the six-tablet pack for
treatment of malaria in patients who need a 24-tablet
pack or splitting the blister pack into 12-tablet pack for
a child weighing 9 kg might result into uncertainty in
the use of the drug as per its recommended regimen.
Simplified packaging of anti-malarials has been found to






Other forms of ACT 3.20 1.34
Quinine 0.54 0.40
AL, artemether-lumefantrine; ACT, artemisinin-based combination therapy.
Affordability was expressed as median price (numerator) against lowest daily
disposable income level (at KES 150, USD 1.875 = denominator).study carried out in Uganda showed that patients’ adher-
ence was high when they received AL blister packs with
a weight-specific number of tablets and including pictor-
ial instructions on how to use it [28]. This observation
was also recorded in a study in the coastal region of
Kenya, where simplicity of drug regimen was associated
with increased treatment adherence [29].
The current study findings, consistent with previous
ones [20] observed that lack of drugs in the formal sector
contributes to people buying drugs from non-formal out-
lets. In such informal set-ups, the quality of drugs is less
controlled and information on dose is not often provided.
Yet in another study, about a third of individuals who
sought care from public health facilities did not get drugs
from the hospital pharmacy because they were out of
stock [30]. The high stock-out rates questions the logic be-
hind WHO’s call to treat malaria cases within 24 hours.
Further questions are also raised on the recommendation
to treat only laboratory-confirmed malaria cases, as well
as confining ACT to formal sector providers, since these
drugs are inaccessible especially in the rural areas, a part
poorly covered by these facilities. Unless the communities
are involved in the implementation of these guidelines, the
current trend in malaria treatment in this region might
start leaning towards the negative.
The prices of subsidized ACT remained lower than
other anti-malarials in all the outlets. The lower median
price in not-for-profit outlets was as a result of this sector
being supplied with subsidized ACT by the government.
In this sector, there was a full adherence to the subsidy
policy as much as the anti-malarials were not free as in
the public outlets. The not-for-profit outlets had add-
itional service charge, further raising the price of the
drugs. Lower prices of subsidized ACT are highly com-
mendable, although it is not affordable to people who are
of lowest economic levels. For instance, buying a full
course of subsidized ACT would cost USD 0.94 in private
and USD 0.75 in not-for-profit outlets, thus requiring up to
0.5 and 0.4 days of disposable household income, respect-
ively. These observations from private outlets are consistent
with previous data obtained from Kenya, Madagascar and
Tanzania while the observed prices in the current study are
lower than for Ghana, Zanzibar, Niger, Nigeria and Uganda
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in which the median prices ranged from USD 0.58 to USD
1.96 [31]. Conversely, the price of first-line treatment in
the current study is higher than the price of first-line treat-
ment in Burundi which was USD 0.16 in 2011 [26].
Higher prices than recommended in private outlets in-
dicate lack of regulations and price control. This lack of
control affects public health in the society, especially the
most vulnerable groups to malaria-related morbidity and
mortality due to poverty [32]. However, the price differ-
ences between the private and not-for-profit outlets for
both subsidized ACT and quinine need to be reconsid-
ered. Given the 3.2-fold price differences of other forms
of ACT in the private outlets as compared to the not-
for-profit outlets, there is need to lower these prices in
the private outlets to make them comparable to those in
other outlets. The reasons for reconciling and regulating
prices may range from the fact that many households
bought anti-malarials from private outlets due to fre-
quent stock-outs in the public outlets. Secondly, the
price is a vital factor in determining how drugs are used
in the household. Thirdly, the private outlets are more
accessible in terms of distance, as it has been previously
demonstrated in a study in this region [16]. Considering
the three reasons which show evidence of the role played
by private sector in providing treatment for patients in
western Kenya, it is important to effectively increase the
affordability of other artemisinin-based combinations in
these outlets. This strategy would further increase adher-
ence to treatment regimen since the affected population
would be able to afford the full course of anti-malarials.
The end results would be among other reasons, prevent-
ing the irrational use of drugs, hence slowing down the
development of resistance by malarial parasite. The ob-
servations in the current study fully support the WHO
echoes that when health systems are not able to provide
ACT at little or no cost, consumers may have to pur-
chase them in the private sector [4].Conclusion
Availability of anti-malarials (ACT and quinine) still re-
mains a challenge in the outlets in malaria endemic regions
of western Kenya. First-line therapy for uncomplicated
malaria, the subsidized ACT, was more available in public
and not-for-profit facilities although with frequent stock-
outs reported in public outlets. The prices remains high in
the private outlets despite the fact that more households
get their drugs from this sector hence making affordability
a challenge. Private-sector marketing of ACT has resulted
into use of sub-optimal doses because of partial sales of
course of treatment packages. Collectively, availability,
price and affordability of the drugs affect adherence to the
dosing schedules during the treatment course.Recommendations
The study is in support of programmes that can support
the subsidy policy and should be recommends that the
programmes should be extended to include other anti-
malarials to make them affordable in all sector outlets.
In addition, frequent stock-outs of the required anti-
malarials for different weight groups calls for more em-
phasis on the implementation of malaria treatment
policy. It is highly advised that a creation of private-
public partnership in the procurement and distribution
of recommended anti-malaria drugs is the goal to make
them available for the customers in all the outlets. The
factors that influence availability should be tackled accord-
ing to regional context. These should include monitoring
net sales/consumption rates through inventory, time
frame estimates and physical stock recording, especially
according to seasonality of illness and differences in dis-
trict health needs. Internal agreement to transfer anti-
malarials from one sector outlet to another and from
one region to another depending on the disease burden
and consumption rate is proposed.
The government needs to implement price regulatory
policies to protect the most vulnerable groups from ex-
ploitation by establishing effective surveillance mecha-
nisms. The prices should also be regulated to ensure
uniformity in pricing of the same product in all sector
outlets. Finally, appropriate health promotion programmes
on the importance of anti-malarial adherence can be made
available to the community. This could be done, for ex-
ample, through pamphlets in medical facilities, regular
public service announcements and mass media includ-
ing use of television, radio and video shows or through
a more community-focused method. Following a switch
in national drug policy to ACT, behaviour change com-
munication is recommended during which all outlets
staff should be trained in unbiased manner on the
current malaria policy to improve drug use in the com-
munity. In areas where such interventions have been
performed, then further scaling up of these programmes
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